Neurology:他汀类药物或由较低几率的大脑动脉粥样硬化介导,可降低成年人患帕金森综合征风险!

2022-04-03 Naomi MedSci原创

近日,研究人员证实使用他汀类药物的成年人患帕金森综合症的风险较低。这种风险可能部分由较低几率的大脑动脉粥样硬化所介导,这突出脑血管疾病在晚年帕金森综合征中的作用,并表明他汀类药物降低其几率的潜在作用。

运动障碍常见于老年人。部分成年人表现出力量的丧失,或步态、平衡障碍,许多成年人还表现出轻微的帕金森症状。这些症状包括帕金森病步态、运动迟缓、颤抖和僵硬。帕金森症状在大约50% 的老年人身上很常见。此外,这些征兆并非良性,因为它们与不良健康结果相关,包括跌倒、残疾、痴呆和死亡。虽然帕金森病(PD)可能是运动障碍专家认为最常见的帕金森综合症的病因,但PD只影响不到5% 的普通民众,并不常见。因此,单纯的PD病理学不能解释在社区老年人中报道的帕金森综合症的严重程度。此外,对于帕金森病及其潜在的神经病理学没有疾病修饰治疗。

累积的脑成像和尸检研究显示,在居住在社区的老年人中,不同的脑血管疾病(CVD)病理通常与进行性帕金森综合征有关,帕金森综合征病理学仅在少数患有帕金森综合征的老年人中观察到。这些发现具有重要的临床意义,因为它们表明,减少心血管疾病的干预措施可能会降低老年人群帕金森病的严重程度。

他汀类药物通过减少脑血管动脉硬化来预防中风,在一般人群中对减少中风发挥了重要作用。近日,有研究人员检验了使用他汀类药物的老年人患帕金森综合症的风险较低的假设。该研究的主要问题是他汀类药物是否与老年人发生帕金森综合症的风险降低有关,以及这种关联是否是通过他汀类药物对大脑动脉粥样硬化的影响而介导的。

研究方法:

研究针对老年人进行,即每年对4种帕金森症状进行临床测试,并根据对所有药物的检查评估他汀类药物的使用。如果有 2 个或更多帕金森症状的临床证据,则存在帕金森病。死后脑部检查收集病理指标,包括wilis大血管的动脉粥样硬化。检查了基线他汀类药物的使用是否与帕金森综合征相关。然后在死者中,检查了死前他汀类药物的使用是否与病理有关,以及病理是否将他汀类药物的使用与帕金森病的关联联系起来。

研究结果:

  • 研究基线时参与者 (n=2841) 的平均年龄为 76.3 (SD=7.4) 岁,其中 75% 为女性。 在 6 年的平均随访期间(平均值 = 5.6,SD = 4.9),50%(n = 1432)的参与者发展为帕金森症。
  • 基线时使用他汀类药物 (n=936) 与较低的帕金森症风险相关 (HR=0.84, 95%CI: 0.74–0.96, p=0.008),控制人口统计学、血管危险因素和疾病。
  • 在死者 [n=1044,死亡年龄(平均值=89.2,SD=6.7)] 中,死前使用他汀类药物与动脉粥样硬化的几率(OR=0.63, 95%CI: 0.50–0.79, p<0.001)。
  • 在中介分析中,直接 (OR=0.73, 95%CI: 0.54–0.93, p=0.008) 和间接 (OR=0.92, 95%CI: 0.88–0.97, p=0.002) 途径均通过不太严重的动脉粥样硬化将他汀类药物与帕金森症联系起来,表明动脉粥样硬化介导了他汀类药物与帕金森症之间 17% 的关联。

使用他汀类药物的成年人患帕金森综合症的风险较低,而这种风险可能部分由较低几率的大脑动脉粥样硬化所介导。这些发现突出了脑血管疾病在晚年帕金森综合征中的作用,并表明他汀类药物在降低其剂量方面的潜在作用。

这项研究提供了一级证据,证明他汀类药物的使用与老年人患帕金森综合症的风险降低有关。

文献来源:Oveisgharan S, Yu L, Barnes LL, et al. Association of Statins With Cerebral Atherosclerosis and Incident Parkinsonism in Older Adults [published online ahead of print, 2022 Mar 23]. Neurology. 2022;10.1212/WNL.0000000000200182. doi:10.1212/WNL.0000000000200182

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (15)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2001774, encodeId=c8802001e7472, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Jul 04 12:55:14 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944744, encodeId=24431944e44d5, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Oct 15 15:55:14 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044642, encodeId=4545204464228, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Tue Apr 19 04:55:14 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665729, encodeId=2ac71665e2943, content=<a href='/topic/show?id=de2a485385f' target=_blank style='color:#2F92EE;'>#帕金森综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48538, encryptionId=de2a485385f, topicName=帕金森综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43d925986347, createdName=12498f1em16(暂无昵称), createdTime=Wed Aug 24 04:55:14 CST 2022, time=2022-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928885, encodeId=a8541928885ec, content=<a href='/topic/show?id=dc1a84e431e' target=_blank style='color:#2F92EE;'>#脑动脉粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84743, encryptionId=dc1a84e431e, topicName=脑动脉粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Tue Aug 30 17:55:14 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208388, encodeId=45b6120838802, content=拓展阅读为什么打不开?, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Sun Apr 03 17:24:15 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208323, encodeId=b3091208323ca, content=下边的相关资料无法打开, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0eb2046086, createdName=1881eacd07m, createdTime=Sun Apr 03 10:48:54 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208304, encodeId=3580120830441, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b9d2233692, createdName=1212ba38m22暂无昵称, createdTime=Sun Apr 03 10:21:59 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208278, encodeId=dbd912082e856, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/02/28/889a1910ded7780f3c049b354f1648b7.jpg, createdBy=2a791737770, createdName=mswert122, createdTime=Sun Apr 03 04:34:29 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207799, encodeId=d758120e799a5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce804788727, createdName=247593158, createdTime=Fri Apr 01 11:03:40 CST 2022, time=2022-04-01, status=1, ipAttribution=)]
    2022-07-04 yinhl1978
  2. [GetPortalCommentsPageByObjectIdResponse(id=2001774, encodeId=c8802001e7472, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Jul 04 12:55:14 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944744, encodeId=24431944e44d5, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Oct 15 15:55:14 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044642, encodeId=4545204464228, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Tue Apr 19 04:55:14 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665729, encodeId=2ac71665e2943, content=<a href='/topic/show?id=de2a485385f' target=_blank style='color:#2F92EE;'>#帕金森综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48538, encryptionId=de2a485385f, topicName=帕金森综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43d925986347, createdName=12498f1em16(暂无昵称), createdTime=Wed Aug 24 04:55:14 CST 2022, time=2022-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928885, encodeId=a8541928885ec, content=<a href='/topic/show?id=dc1a84e431e' target=_blank style='color:#2F92EE;'>#脑动脉粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84743, encryptionId=dc1a84e431e, topicName=脑动脉粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Tue Aug 30 17:55:14 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208388, encodeId=45b6120838802, content=拓展阅读为什么打不开?, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Sun Apr 03 17:24:15 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208323, encodeId=b3091208323ca, content=下边的相关资料无法打开, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0eb2046086, createdName=1881eacd07m, createdTime=Sun Apr 03 10:48:54 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208304, encodeId=3580120830441, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b9d2233692, createdName=1212ba38m22暂无昵称, createdTime=Sun Apr 03 10:21:59 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208278, encodeId=dbd912082e856, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/02/28/889a1910ded7780f3c049b354f1648b7.jpg, createdBy=2a791737770, createdName=mswert122, createdTime=Sun Apr 03 04:34:29 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207799, encodeId=d758120e799a5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce804788727, createdName=247593158, createdTime=Fri Apr 01 11:03:40 CST 2022, time=2022-04-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2001774, encodeId=c8802001e7472, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Jul 04 12:55:14 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944744, encodeId=24431944e44d5, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Oct 15 15:55:14 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044642, encodeId=4545204464228, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Tue Apr 19 04:55:14 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665729, encodeId=2ac71665e2943, content=<a href='/topic/show?id=de2a485385f' target=_blank style='color:#2F92EE;'>#帕金森综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48538, encryptionId=de2a485385f, topicName=帕金森综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43d925986347, createdName=12498f1em16(暂无昵称), createdTime=Wed Aug 24 04:55:14 CST 2022, time=2022-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928885, encodeId=a8541928885ec, content=<a href='/topic/show?id=dc1a84e431e' target=_blank style='color:#2F92EE;'>#脑动脉粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84743, encryptionId=dc1a84e431e, topicName=脑动脉粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Tue Aug 30 17:55:14 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208388, encodeId=45b6120838802, content=拓展阅读为什么打不开?, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Sun Apr 03 17:24:15 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208323, encodeId=b3091208323ca, content=下边的相关资料无法打开, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0eb2046086, createdName=1881eacd07m, createdTime=Sun Apr 03 10:48:54 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208304, encodeId=3580120830441, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b9d2233692, createdName=1212ba38m22暂无昵称, createdTime=Sun Apr 03 10:21:59 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208278, encodeId=dbd912082e856, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/02/28/889a1910ded7780f3c049b354f1648b7.jpg, createdBy=2a791737770, createdName=mswert122, createdTime=Sun Apr 03 04:34:29 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207799, encodeId=d758120e799a5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce804788727, createdName=247593158, createdTime=Fri Apr 01 11:03:40 CST 2022, time=2022-04-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2001774, encodeId=c8802001e7472, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Jul 04 12:55:14 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944744, encodeId=24431944e44d5, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Oct 15 15:55:14 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044642, encodeId=4545204464228, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Tue Apr 19 04:55:14 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665729, encodeId=2ac71665e2943, content=<a href='/topic/show?id=de2a485385f' target=_blank style='color:#2F92EE;'>#帕金森综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48538, encryptionId=de2a485385f, topicName=帕金森综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43d925986347, createdName=12498f1em16(暂无昵称), createdTime=Wed Aug 24 04:55:14 CST 2022, time=2022-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928885, encodeId=a8541928885ec, content=<a href='/topic/show?id=dc1a84e431e' target=_blank style='color:#2F92EE;'>#脑动脉粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84743, encryptionId=dc1a84e431e, topicName=脑动脉粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Tue Aug 30 17:55:14 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208388, encodeId=45b6120838802, content=拓展阅读为什么打不开?, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Sun Apr 03 17:24:15 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208323, encodeId=b3091208323ca, content=下边的相关资料无法打开, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0eb2046086, createdName=1881eacd07m, createdTime=Sun Apr 03 10:48:54 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208304, encodeId=3580120830441, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b9d2233692, createdName=1212ba38m22暂无昵称, createdTime=Sun Apr 03 10:21:59 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208278, encodeId=dbd912082e856, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/02/28/889a1910ded7780f3c049b354f1648b7.jpg, createdBy=2a791737770, createdName=mswert122, createdTime=Sun Apr 03 04:34:29 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207799, encodeId=d758120e799a5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce804788727, createdName=247593158, createdTime=Fri Apr 01 11:03:40 CST 2022, time=2022-04-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2001774, encodeId=c8802001e7472, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Jul 04 12:55:14 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944744, encodeId=24431944e44d5, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Oct 15 15:55:14 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044642, encodeId=4545204464228, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Tue Apr 19 04:55:14 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665729, encodeId=2ac71665e2943, content=<a href='/topic/show?id=de2a485385f' target=_blank style='color:#2F92EE;'>#帕金森综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48538, encryptionId=de2a485385f, topicName=帕金森综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43d925986347, createdName=12498f1em16(暂无昵称), createdTime=Wed Aug 24 04:55:14 CST 2022, time=2022-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928885, encodeId=a8541928885ec, content=<a href='/topic/show?id=dc1a84e431e' target=_blank style='color:#2F92EE;'>#脑动脉粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84743, encryptionId=dc1a84e431e, topicName=脑动脉粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Tue Aug 30 17:55:14 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208388, encodeId=45b6120838802, content=拓展阅读为什么打不开?, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Sun Apr 03 17:24:15 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208323, encodeId=b3091208323ca, content=下边的相关资料无法打开, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0eb2046086, createdName=1881eacd07m, createdTime=Sun Apr 03 10:48:54 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208304, encodeId=3580120830441, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b9d2233692, createdName=1212ba38m22暂无昵称, createdTime=Sun Apr 03 10:21:59 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208278, encodeId=dbd912082e856, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/02/28/889a1910ded7780f3c049b354f1648b7.jpg, createdBy=2a791737770, createdName=mswert122, createdTime=Sun Apr 03 04:34:29 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207799, encodeId=d758120e799a5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce804788727, createdName=247593158, createdTime=Fri Apr 01 11:03:40 CST 2022, time=2022-04-01, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2001774, encodeId=c8802001e7472, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Jul 04 12:55:14 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944744, encodeId=24431944e44d5, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Oct 15 15:55:14 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044642, encodeId=4545204464228, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Tue Apr 19 04:55:14 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665729, encodeId=2ac71665e2943, content=<a href='/topic/show?id=de2a485385f' target=_blank style='color:#2F92EE;'>#帕金森综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48538, encryptionId=de2a485385f, topicName=帕金森综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43d925986347, createdName=12498f1em16(暂无昵称), createdTime=Wed Aug 24 04:55:14 CST 2022, time=2022-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928885, encodeId=a8541928885ec, content=<a href='/topic/show?id=dc1a84e431e' target=_blank style='color:#2F92EE;'>#脑动脉粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84743, encryptionId=dc1a84e431e, topicName=脑动脉粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Tue Aug 30 17:55:14 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208388, encodeId=45b6120838802, content=拓展阅读为什么打不开?, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Sun Apr 03 17:24:15 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208323, encodeId=b3091208323ca, content=下边的相关资料无法打开, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0eb2046086, createdName=1881eacd07m, createdTime=Sun Apr 03 10:48:54 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208304, encodeId=3580120830441, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b9d2233692, createdName=1212ba38m22暂无昵称, createdTime=Sun Apr 03 10:21:59 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208278, encodeId=dbd912082e856, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/02/28/889a1910ded7780f3c049b354f1648b7.jpg, createdBy=2a791737770, createdName=mswert122, createdTime=Sun Apr 03 04:34:29 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207799, encodeId=d758120e799a5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce804788727, createdName=247593158, createdTime=Fri Apr 01 11:03:40 CST 2022, time=2022-04-01, status=1, ipAttribution=)]
    2022-04-03 weigq

    拓展阅读为什么打不开?

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2001774, encodeId=c8802001e7472, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Jul 04 12:55:14 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944744, encodeId=24431944e44d5, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Oct 15 15:55:14 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044642, encodeId=4545204464228, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Tue Apr 19 04:55:14 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665729, encodeId=2ac71665e2943, content=<a href='/topic/show?id=de2a485385f' target=_blank style='color:#2F92EE;'>#帕金森综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48538, encryptionId=de2a485385f, topicName=帕金森综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43d925986347, createdName=12498f1em16(暂无昵称), createdTime=Wed Aug 24 04:55:14 CST 2022, time=2022-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928885, encodeId=a8541928885ec, content=<a href='/topic/show?id=dc1a84e431e' target=_blank style='color:#2F92EE;'>#脑动脉粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84743, encryptionId=dc1a84e431e, topicName=脑动脉粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Tue Aug 30 17:55:14 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208388, encodeId=45b6120838802, content=拓展阅读为什么打不开?, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Sun Apr 03 17:24:15 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208323, encodeId=b3091208323ca, content=下边的相关资料无法打开, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0eb2046086, createdName=1881eacd07m, createdTime=Sun Apr 03 10:48:54 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208304, encodeId=3580120830441, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b9d2233692, createdName=1212ba38m22暂无昵称, createdTime=Sun Apr 03 10:21:59 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208278, encodeId=dbd912082e856, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/02/28/889a1910ded7780f3c049b354f1648b7.jpg, createdBy=2a791737770, createdName=mswert122, createdTime=Sun Apr 03 04:34:29 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207799, encodeId=d758120e799a5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce804788727, createdName=247593158, createdTime=Fri Apr 01 11:03:40 CST 2022, time=2022-04-01, status=1, ipAttribution=)]
    2022-04-03 1881eacd07m

    下边的相关资料无法打开

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2001774, encodeId=c8802001e7472, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Jul 04 12:55:14 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944744, encodeId=24431944e44d5, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Oct 15 15:55:14 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044642, encodeId=4545204464228, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Tue Apr 19 04:55:14 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665729, encodeId=2ac71665e2943, content=<a href='/topic/show?id=de2a485385f' target=_blank style='color:#2F92EE;'>#帕金森综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48538, encryptionId=de2a485385f, topicName=帕金森综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43d925986347, createdName=12498f1em16(暂无昵称), createdTime=Wed Aug 24 04:55:14 CST 2022, time=2022-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928885, encodeId=a8541928885ec, content=<a href='/topic/show?id=dc1a84e431e' target=_blank style='color:#2F92EE;'>#脑动脉粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84743, encryptionId=dc1a84e431e, topicName=脑动脉粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Tue Aug 30 17:55:14 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208388, encodeId=45b6120838802, content=拓展阅读为什么打不开?, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Sun Apr 03 17:24:15 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208323, encodeId=b3091208323ca, content=下边的相关资料无法打开, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0eb2046086, createdName=1881eacd07m, createdTime=Sun Apr 03 10:48:54 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208304, encodeId=3580120830441, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b9d2233692, createdName=1212ba38m22暂无昵称, createdTime=Sun Apr 03 10:21:59 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208278, encodeId=dbd912082e856, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/02/28/889a1910ded7780f3c049b354f1648b7.jpg, createdBy=2a791737770, createdName=mswert122, createdTime=Sun Apr 03 04:34:29 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207799, encodeId=d758120e799a5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce804788727, createdName=247593158, createdTime=Fri Apr 01 11:03:40 CST 2022, time=2022-04-01, status=1, ipAttribution=)]
    2022-04-03 1212ba38m22暂无昵称

    学习了

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2001774, encodeId=c8802001e7472, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Jul 04 12:55:14 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944744, encodeId=24431944e44d5, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Oct 15 15:55:14 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044642, encodeId=4545204464228, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Tue Apr 19 04:55:14 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665729, encodeId=2ac71665e2943, content=<a href='/topic/show?id=de2a485385f' target=_blank style='color:#2F92EE;'>#帕金森综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48538, encryptionId=de2a485385f, topicName=帕金森综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43d925986347, createdName=12498f1em16(暂无昵称), createdTime=Wed Aug 24 04:55:14 CST 2022, time=2022-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928885, encodeId=a8541928885ec, content=<a href='/topic/show?id=dc1a84e431e' target=_blank style='color:#2F92EE;'>#脑动脉粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84743, encryptionId=dc1a84e431e, topicName=脑动脉粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Tue Aug 30 17:55:14 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208388, encodeId=45b6120838802, content=拓展阅读为什么打不开?, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Sun Apr 03 17:24:15 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208323, encodeId=b3091208323ca, content=下边的相关资料无法打开, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0eb2046086, createdName=1881eacd07m, createdTime=Sun Apr 03 10:48:54 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208304, encodeId=3580120830441, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b9d2233692, createdName=1212ba38m22暂无昵称, createdTime=Sun Apr 03 10:21:59 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208278, encodeId=dbd912082e856, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/02/28/889a1910ded7780f3c049b354f1648b7.jpg, createdBy=2a791737770, createdName=mswert122, createdTime=Sun Apr 03 04:34:29 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207799, encodeId=d758120e799a5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce804788727, createdName=247593158, createdTime=Fri Apr 01 11:03:40 CST 2022, time=2022-04-01, status=1, ipAttribution=)]
    2022-04-03 mswert122

    学习一下

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2001774, encodeId=c8802001e7472, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Jul 04 12:55:14 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944744, encodeId=24431944e44d5, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Oct 15 15:55:14 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044642, encodeId=4545204464228, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Tue Apr 19 04:55:14 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665729, encodeId=2ac71665e2943, content=<a href='/topic/show?id=de2a485385f' target=_blank style='color:#2F92EE;'>#帕金森综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48538, encryptionId=de2a485385f, topicName=帕金森综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43d925986347, createdName=12498f1em16(暂无昵称), createdTime=Wed Aug 24 04:55:14 CST 2022, time=2022-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928885, encodeId=a8541928885ec, content=<a href='/topic/show?id=dc1a84e431e' target=_blank style='color:#2F92EE;'>#脑动脉粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84743, encryptionId=dc1a84e431e, topicName=脑动脉粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Tue Aug 30 17:55:14 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208388, encodeId=45b6120838802, content=拓展阅读为什么打不开?, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Sun Apr 03 17:24:15 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208323, encodeId=b3091208323ca, content=下边的相关资料无法打开, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0eb2046086, createdName=1881eacd07m, createdTime=Sun Apr 03 10:48:54 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208304, encodeId=3580120830441, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b9d2233692, createdName=1212ba38m22暂无昵称, createdTime=Sun Apr 03 10:21:59 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208278, encodeId=dbd912082e856, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/02/28/889a1910ded7780f3c049b354f1648b7.jpg, createdBy=2a791737770, createdName=mswert122, createdTime=Sun Apr 03 04:34:29 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207799, encodeId=d758120e799a5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce804788727, createdName=247593158, createdTime=Fri Apr 01 11:03:40 CST 2022, time=2022-04-01, status=1, ipAttribution=)]
    2022-04-01 247593158

    学习了

    0

相关资讯

JACC:中度强度运动训练可改善他汀类药物使用者的骨骼肌表现

中等强度的耐力和抗阻力运动训练可以改善他汀类药物服用者的肌肉性能、毛细血管化和线粒体含量,且不会加重肌肉不适

JAMA Oncol:他汀类药物对前列腺癌筛查的影响

他汀类药物的使用不会损害基于 PSA 的前列腺癌筛查获益

JAHA:他汀类药物与SARS-CoV-2感染

与不服用他汀类药物的患者相比,服用他汀类药物的患者SARS-CoV-2检测呈阳性的风险相同,而75岁以下的患者在检测呈阳性的30天内具有相似的结局。

JAMA neuro:证据来啦——强化降脂真的能预防二次中风,还能减少心血管病风险!

低密度脂蛋白胆固醇(LDL-C)水平升高是心血管疾病(包括缺血性卒中)的一个危险因素。

Circulation:他汀类药物用于心血管疾病的预防,获益不止10年!

仿制药的定价使许多成年人的预防性他汀治疗具有成本效益。

Atherosclerosis:他汀类药物用于一级预防的指南标准与RCT证据研究

所有关于他汀类药物用于动脉粥样硬化性心血管疾病(ASCVD)一级预防的主要国际指南都遵循基于预测的ASCVD绝对风险进行对应治疗的原则。

拓展阅读

Nat Commun 山东大学齐鲁医院王双喜教授团队揭示他汀类药物能改善射血分数保留的心力衰竭

该研究揭示他汀类药物通过上调心脏内皮细胞环状RNA-RBCK1的表达,改善心脏舒张功能,为HFpEF的药物治疗提供了新思路。

Diabetes Metab Syndr Obes:某三级医院2型糖尿病患者他汀类药物适应证及剂量强化评价

研究发现约2/3的患者可以适当加大他汀类药物的剂量。但糖尿病病程较长、男性和高龄以及血压控制不佳的患者仍需要进行监测。

CGP指南|《他汀类药物用于成年人心血管疾病的一级预防:美国预防临床服务指南工作组推荐声明》解读

通过对该指南的解读,我们可以更好地了解他汀类药物的适应证、用药剂量和注意事项,为临床医生和患者提供更加科学的用药依据。

Cell Metab:吴岳/袁祖贻/于君合作揭示他汀类药物引起高血糖的潜在机制

该研究表明他汀类药物通过以微生物群依赖性方式降低血胰高血糖素样肽-1水平来加重胰岛素抵抗。

JAHA:他汀类药物治疗与房颤患者心力衰竭风险降低相关

人口老龄化,以及高血压和糖尿病等慢性疾病的日益流行,正在推动全球房颤的患病率高涨。服用他汀类药物与房颤患者发生HF的风险降低相关,并呈时间依赖性。

第31届欧洲消化疾病周(UEGW) 2023:他汀类药物联合标准三联疗法或可提高幽门螺杆菌感染的根除率!

阿托伐他汀配合标准三联疗法可显著提高幽门螺杆菌感染的根除率,且无临床重要不良事件。

2020 EANM/SNMMI实践指南:帕金森综合征多巴胺能影像检查

欧洲核医学协会(EANM,European Association of Nuclear Medicine) · 2020-05-09